{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T20:06:06.573671+00:00","company":{"ticker":"TMDX","cik":1756262,"company_name":"TransMedics Group, Inc."},"pagination":{"limit":100,"returned":8,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"29499b05aaf56946d5526ca17d57a8ae26ce6a6a","cik":1756262,"ticker":"TMDX","company_name":"TransMedics Group, Inc.","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":"$0.20 per fully diluted share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$7.3 million","period_text":"the quarter ended March 31, 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":"$173.9 million"},"claim":"TransMedics Group, Inc. reported the quarter ended March 31, 2026 results: revenue $173.9 million, net income $7.3 million, EPS $0.20 per fully diluted share. Guidance reaffirmed.","evidence_excerpt":"Total revenue of $173.9 million in the first quarter of 2026, a 21% increase compared to the first quarter of 2025 ▪ Net income of $7.3 million or $0.20 per fully diluted share in the first quarter of 2026","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-206347","anchor_url":"https://secwatch.observer/filing/0001193125-26-206347#claim-29499b05aaf56946d5526ca17d57a8ae26ce6a6a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1756262/000119312526206347/0001193125-26-206347-index.htm"},{"fact_type":"material_agreement","fact_key":"876453fef24e7b560802d8caf9184d1656c5057c","cik":1756262,"ticker":"TMDX","company_name":"TransMedics Group, Inc.","filed_at":"2026-01-12T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Lease","agreement_type":"lease","counterparty":"BioMed Realty","effective_date":"2026-01-08","item_codes_triggered":["1.01"],"value_text":"approximately $23.9 million"},"claim":"TransMedics Group, Inc. entered into Lease with BioMed Realty valued at approximately $23.9 million (effective 2026-01-08).","evidence_excerpt":"On January 8, 2026, TransMedics Group, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with BioMed Realty (the “Landlord”) for the lease of approximately 498,286 square feet of space located at 188 Assembly Park Drive, Somerville, MA 02145 (the “Premises”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-009816","anchor_url":"https://secwatch.observer/filing/0001193125-26-009816#claim-876453fef24e7b560802d8caf9184d1656c5057c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1756262/000119312526009816/0001193125-26-009816-index.htm"},{"fact_type":"ma_transaction","fact_key":"ad602c3cf05f0448592fffc363c1eeac514fb23f","cik":1756262,"ticker":"TMDX","company_name":"TransMedics Group, Inc.","filed_at":"2025-10-06T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2025-10-03","consideration_text":"approximately $14.5 million","counterparty":"Teaghlach Aviation, LLC","effective_date":"2025-10-03","item_codes_triggered":["2.01"]},"claim":"TransMedics Group, Inc. completed an acquisition involving Teaghlach Aviation, LLC for approximately $14.5 million (closed 2025-10-03).","evidence_excerpt":"on October 3, 2025, the Buyer acquired a fixed-wing aircraft from Teaghlach Aviation, LLC for a purchase price of approximately $14.5 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-231900","anchor_url":"https://secwatch.observer/filing/0001193125-25-231900#claim-ad602c3cf05f0448592fffc363c1eeac514fb23f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1756262/000119312525231900/0001193125-25-231900-index.htm"},{"fact_type":"earnings_release","fact_key":"2f320818e85485f42d06e276ce838248f56807cb","cik":1756262,"ticker":"TMDX","company_name":"TransMedics Group, Inc.","filed_at":"2024-04-30T23:59:59+00:00","payload":{"eps_text":"$0.35 per fully diluted share","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$12.2 million","period_text":"quarter ended March 31, 2024","report_date":"2024-04-30","result_type":"reported_results","revenue_text":"$96.9 million"},"claim":"TransMedics Group, Inc. reported quarter ended March 31, 2024 results: revenue $96.9 million, net income $12.2 million, EPS $0.35 per fully diluted share. Guidance raised.","evidence_excerpt":"Net revenue of $96.9 million in the first quarter of 2024, a 133% increase compared to the first quarter of 2023","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-24-050568","anchor_url":"https://secwatch.observer/filing/0000950170-24-050568#claim-2f320818e85485f42d06e276ce838248f56807cb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1756262/000095017024050568/0000950170-24-050568-index.htm"},{"fact_type":"ma_transaction","fact_key":"a3b018e1ea1065013aa64590476aaf94a510dcb9","cik":1756262,"ticker":"TMDX","company_name":"TransMedics Group, Inc.","filed_at":"2024-03-12T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2024-03-08","consideration_text":"approximately $12.5 million","counterparty":"Evans General Aviation, LLC","effective_date":"2024-03-08","item_codes_triggered":["2.01"]},"claim":"TransMedics Group, Inc. completed an acquisition involving Evans General Aviation, LLC for approximately $12.5 million (closed 2024-03-08).","evidence_excerpt":"on March 8, 2024, the Buyer acquired a fixed-wing aircraft from Evans General Aviation, LLC for a purchase price of approximately $12.5 million (together with the Prior Acquisitions, the “Acquisitions”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-24-065858","anchor_url":"https://secwatch.observer/filing/0001193125-24-065858#claim-a3b018e1ea1065013aa64590476aaf94a510dcb9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1756262/000119312524065858/0001193125-24-065858-index.htm"},{"fact_type":"earnings_release","fact_key":"604d3a545f93e554ef5b26dc6907d723fde3f3f1","cik":1756262,"ticker":"TMDX","company_name":"TransMedics Group, Inc.","filed_at":"2024-02-26T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full-year 2024","report_date":"2024-02-26","result_type":"guidance_update","revenue_text":"$360 million to $370 million"},"claim":"TransMedics Group, Inc. reported full-year 2024 results: revenue $360 million to $370 million. Guidance initiated.","evidence_excerpt":"TransMedics expects total revenue for full-year 2024 to be in the range of $360 million to $370 million, which represents 49% to 53% growth compared to the company’s prior year revenue.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-020175","anchor_url":"https://secwatch.observer/filing/0000950170-24-020175#claim-604d3a545f93e554ef5b26dc6907d723fde3f3f1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1756262/000095017024020175/0000950170-24-020175-index.htm"},{"fact_type":"earnings_release","fact_key":"52b948d073e61605b83459e2535ab14e48a1ee0d","cik":1756262,"ticker":"TMDX","company_name":"TransMedics Group, Inc.","filed_at":"2024-02-26T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$(25.0) million","period_text":"the year ended December 31, 2023","report_date":"2024-02-26","result_type":"reported_results","revenue_text":"$241.6 million"},"claim":"TransMedics Group, Inc. reported the year ended December 31, 2023 results: revenue $241.6 million, net income $(25.0) million.","evidence_excerpt":"December 31, 2023. Recent Highlights ▪ Total revenue of $81.2 million in the fourth quarter of 2023, a 159% increase compared to the fourth quarter of 2022 ▪ Total revenue of $241.6 million in the full year of 2023, a 159% increase compared to the full year of 2022 ▪ Generated net income of $4.0 million or $0.12 per share in the fourth quarter of 2023 “2023 was a","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-020175","anchor_url":"https://secwatch.observer/filing/0000950170-24-020175#claim-52b948d073e61605b83459e2535ab14e48a1ee0d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1756262/000095017024020175/0000950170-24-020175-index.htm"},{"fact_type":"earnings_release","fact_key":"b8cca752114c27c3376d8e0d46cbb1a5f25060cd","cik":1756262,"ticker":"TMDX","company_name":"TransMedics Group, Inc.","filed_at":"2024-02-26T23:59:59+00:00","payload":{"eps_text":"$0.12 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$4.0 million","period_text":"the quarter ended December 31, 2023","report_date":"2024-02-26","result_type":"reported_results","revenue_text":"$81.2 million"},"claim":"TransMedics Group, Inc. reported the quarter ended December 31, 2023 results: revenue $81.2 million, net income $4.0 million, EPS $0.12 per share.","evidence_excerpt":"patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2023. Recent Highlights ▪ Total revenue of $81.2 million in the fourth quarter of 2023, a 159% increase compared to the fourth quarter of 2022 ▪ Total revenue of $241.6 million in the full year of 2023, a 159% increase compared to the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-020175","anchor_url":"https://secwatch.observer/filing/0000950170-24-020175#claim-b8cca752114c27c3376d8e0d46cbb1a5f25060cd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1756262/000095017024020175/0000950170-24-020175-index.htm"}]}